CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
CCX140-B +3 moredrug
Likely dose
CCX140-B 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03536754
NCT03536754Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)

Amgen·interventional·Posted May 25, 2018·Updated Mar 13, 2025

In Brief

A Phase 2 clinical trial evaluating Placebo and CCX140-B for FSGS and 2 related conditions. Completed, enrolled 46 participants across 37 sites in 8 countries.

Detailed Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
CountriesAustralia, Canada, France, Italy, New Zealand, Poland, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 25, 2018
Enrollment StartMay 17, 2018
Primary CompletionFeb 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.1 years ago

Interventions

Placeboother

Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)

CCX140-Bdrug

One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.

CCX140-Bdrug

Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.

CCX140-Bdrug

Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.